Menu

Targos and Ultivue partner to incorporate highly standardized UltiMapper™ tissue multiplex phenotypic assays in support of clinical research services

Targos Molecular Pathology GmbH, a market leader in clinical biomarker services announced today a technology partnership with Ultivue, the innovation leader in multiplex tissue biomarker assays, to offer the biopharmaceutical industry new capabilities to improve the characterization of cancer patients’ samples selected for clinical research programs. 

Ultivue
Nov 12, 2019

UltiMapper multiplex immuno-histochemistry assays enable the precise identification of cellular phenotypes that can be associated to drug efficacy and further used to develop a companion diagnostic assay. 

“UltiMapper assays are very modular by design, allowing for various levels of multiplexing and throughput, and supporting same day staining-to-data workflows,” stated Dr. Thomas Henkel, CEO of Targos. “The adoption of highly standardized multiplex tissue biomarker assays is a strategic fit with our mission to continuously improve the success of clinical trials and deliver exceptional value to our biopharma partners.” 

Ultivue technologies and UltiMapper assays are widely used in tumor immune-profiling research strategies by the biomedical community to demonstrate the clinical utility of panels of markers. “Through our collaboration with Targos, the same panels can seamlessly be used in their existing setup to create a very effective continuum of translational and clinical research,” said Philippe Mourere, SVP Commercial Operations at Ultivue. “Targos also offers highly customizable UltiMapper panels that can be used in combination with the company’s broad menu of additional assays and end-to-end quality services.”

Additional details on the partnership will be communicated at the Society for Immunotherapy of Cancer (SITC) Annual Meeting at the Gaylord National Resort & Convention Center in National Harbor, MD on November 8 and 9, 2019 at the Ultivue booth #428.

June 2020

An Infant's Bounty

Babies amass microbes that can pave the way to a healthy life

Marketplace

Sponsored Product Updates

Imaging Multicolor Western Blots
Introducing The FluorChem R Imaging System
In-House Water Compared to Bottled HPLC-Grade Water
Download this application note to learn how in-house water is an effective option as an HPLC mobile phase!
Considerations to Ensure Optimal Isolation of Single Cells
This review article focuses on the upstream considerations for isolation of individual cells to yield optimal results in single cell applications.
Abingdon Health announces its latest expansion and additional manufacturing capacity
Abingdon Health is pleased to announce further expansion at its York headquarters in the UK, following further investment in state-of-the-art lateral flow automation.